Company: MIRM
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001759425-25-000014
Chunk: 158

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 158
---
0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of December 31, 2024 and 2023— — Common stock, $0.0001 par value; 200,000,000 shares authorized; 48,338,096 and 46,723,143 shares issued and outstanding as of December 31, 2024 and 20235 5 Additional paid-in capital870,189 803,260 Accumulated deficit(644,181)(556,239)Accumulated other comprehensive (loss) income(373)1,644 Total stockholders’ equity225,640 248,670 Total liabilities and stockholders’ equity$670,754 $646,621 

The accompanying notes are an integral part of these consolidated financial statements.

105

Table of Contents

Mirum Pharmaceuticals, Inc.

Consolidated Statements of Operations

(In thousands, except share and per share data)

 Year Ended December 31, 202420232022 Revenue:Product sales, net$336,409 $178,874 $75,062 License and other revenue479 7,500 2,000 Total revenue336,888 186,374 77,062 Operating expenses:Cost of sales81,643 47,039 12,374 Research and development140,630 102,609 106,842 Selling, general and administrative202,221 145,880 89,066 Total operating expenses424,494 295,528 208,282 Loss from operations(87,606)(109,154)(131,220)Other income (expense):Interest income13,792 13,735 3,857 Interest expense(14,311)(15,105)(15,979)Change in fair value of derivative liability— — 906 Loss from termination of revenue interest purchase agreement— (49,076)— Other income (expense), net1,213 (2,824)365 Loss before provision for income taxes(86,912)(162,424)(142,071)Provision for (benefit from) income taxes1,030 991 (6,406)Net loss$(87,942)$(163,415)$(135,665)Net loss per share:Basic$(1.85)$(4.00)$(4.01)Diluted$(